Federated Hermes’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.79M Sell
3,309
-144
-4% -$81.1K ﹤0.01% 1033
2026
Q1
$2.05M Sell
3,453
-41
-1% -$20.4K ﹤0.01% 973
2025
Q4
$1.7M Sell
3,494
-579
-14% -$270K ﹤0.01% 995
2025
Q3
$1.71M Sell
4,073
-173
-4% -$58.2K ﹤0.01% 980
2025
Q2
$1.22M Sell
4,246
-470
-10% -$140K ﹤0.01% 1077
2025
Q1
$1.45M Sell
4,716
-2,362
-33% -$809K ﹤0.01% 1015
2024
Q4
$2.5M Buy
7,078
+305
+5% +$112K 0.01% 886
2024
Q3
$2.43M Sell
6,773
-117
-2% -$39.5K 0.01% 887
2024
Q2
$2.19M Sell
6,890
-733
-10% -$194K 0.01% 903
2024
Q1
$1.75M Sell
7,623
-76
-1% -$17.1K ﹤0.01% 972
2023
Q4
$1.69M Sell
7,699
-916
-11% -$211K ﹤0.01% 996
2023
Q3
$1.95M Sell
8,615
-364
-4% -$83.8K 0.01% 928
2023
Q2
$1.98M Sell
8,979
-34
-0.4% -$7.53K ﹤0.01% 951
2023
Q1
$2.02M Buy
9,013
+24
+0.3% +$5.92K 0.01% 955
2022
Q4
$2.5M Sell
8,989
-3,454
-28% -$872K 0.01% 847
2022
Q3
$2.61M Sell
12,443
-74
-0.6% -$16.5K 0.01% 843
2022
Q2
$2.95M Sell
12,517
-1,086
-8% -$221K 0.01% 826
2022
Q1
$2.44M Buy
13,603
+61
+0.5% +$11.6K 0.01% 987
2021
Q4
$2.93M Buy
13,542
+121
+0.9% +$23.8K 0.01% 956
2021
Q3
$2.48M Buy
13,421
+412
+3% +$81.2K ﹤0.01% 984
2021
Q2
$2.33M Sell
13,009
-5,909
-31% -$1.13M ﹤0.01% 1041
2021
Q1
$3.17M Sell
18,918
-684
-3% -$114K 0.01% 977
2020
Q4
$2.98M Buy
19,602
+148
+0.8% +$19.4K 0.01% 945
2020
Q3
$1.97M Sell
19,454
-190
-1% -$20.8K ﹤0.01% 995
2020
Q2
$2.38M Buy
19,644
+7,953
+68% +$895K 0.01% 938
2020
Q1
$1.11M Sell
11,691
-1,499
-11% -$142K ﹤0.01% 1105
2019
Q4
$1.16M Buy
13,190
+2,791
+27% +$246K ﹤0.01% 1223
2019
Q3
$829K Sell
10,399
-245
-2% -$19.7K ﹤0.01% 1342
2019
Q2
$831K Sell
10,644
-4,168
-28% -$390K ﹤0.01% 1339
2019
Q1
$1.74M Buy
14,812
+1,803
+14% +$210K ﹤0.01% 1103
2018
Q4
$1.42M Sell
13,009
-4,231
-25% -$491K ﹤0.01% 1158
2018
Q3
$2.21M Sell
17,240
-619
-3% -$76.6K 0.01% 1062
2018
Q2
$2.02M Buy
17,859
+33
+0.2% +$3.63K 0.01% 1009
2018
Q1
$2M Buy
17,826
+460
+3% +$58.4K 0.01% 957
2017
Q4
$2.57M Sell
17,366
-6,632
-28% -$843K 0.01% 835
2017
Q3
$2.81M Buy
23,998
+1,361
+6% +$174K 0.01% 772
2017
Q2
$2.94M Sell
22,637
-28,377
-56% -$3.54M 0.01% 747
2017
Q1
$6.91M Sell
51,014
-152,595
-75% -$23.1M 0.02% 497
2016
Q4
$29.2M Sell
203,609
-23,800
-10% -$3.04M 0.09% 192
2016
Q3
$26.9M Sell
227,409
-20,147
-8% -$2.42M 0.08% 206
2016
Q2
$26.2M Buy
247,556
+4,097
+2% +$457K 0.08% 208
2016
Q1
$27.1M Buy
243,459
+51,852
+27% +$6.56M 0.08% 205
2015
Q4
$30M Buy
191,607
+118,326
+161% +$17.2M 0.1% 205
2015
Q3
$9.62M Sell
73,281
-67,157
-48% -$10.8M 0.03% 442
2015
Q2
$24.4M Sell
140,438
-14,564
-9% -$2.62M 0.07% 278
2015
Q1
$26.7M Buy
155,002
+57,475
+59% +$8.76M 0.08% 237
2014
Q4
$12.6M Buy
97,527
+5,067
+5% +$653K 0.04% 395
2014
Q3
$11.9M Sell
92,460
-4,206
-4% -$434K 0.04% 394
2014
Q2
$8.55M Sell
96,666
-10,251
-10% -$986K 0.03% 494
2014
Q1
$10.1M Buy
106,917
+13,027
+14% +$1.33M 0.03% 461
2013
Q4
$10.6M Sell
93,890
-44
-0% -$3.97K 0.04% 432
2013
Q3
$7.41M Sell
93,934
-596
-0.6% -$43.6K 0.03% 461
2013
Q2
$6.22M Buy
+94,530
New +$6.09M 0.02% 511

Other funds holding UTHR

Federated Hermes's UTHR Position: Q2 2026 in Review

Federated Hermes reduced its United Therapeutics (UTHR) stake by 4.2% in Q2 2026, selling an estimated $81.1K and leaving 3,309 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

Federated Hermes first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $30M in Q4 2015. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Federated Hermes held 3,309 shares of United Therapeutics worth $1.79M as of Q2 2026.
  • Federated Hermes sold 144 United Therapeutics shares in Q2 2026, an estimated $81.1K.
  • United Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1033 holding.
  • Federated Hermes first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Federated Hermes's United Therapeutics position peaked at $30M in Q4 2015.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.